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INTRODUCTION
Coagulase-negative staphylococci are commonly isolated bacteria mi-
xed with the more typical ocular flora, and can lead to major infections,
including keratitis, conjunctivitis and endophthalmitis. These infections
represent serious ocular conditions with significant sight-threatening con-
sequences, particularly if aggressive, appropriate therapy is not instituted
in a timely manner(1-4).
In recent years, many new antibiotics and synthetic antimicrobial eye
drops have been developed and used in the treatment of ocular infections.
Any one of these, however, may alter drug sensitivity of bacteria on the
ocular surface. There are many reports in the ophthalmic literature concerning
infections due to methicillin-resistant coagulase-negative staphylococci(5-7).
The quinolones are one class of antibiotics that has been used to treat
these infections, since their introduction into the ophthalmic community in
1991(8-9).
Ciprofloxacin and ofloxacin have soon achieved great acceptance in the
treatment of ocular infections. These antibiotics (ciprofloxacin, ofloxacin,
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Purpose: To evaluate the fluoroquinolone susceptibilities of ocular isolate
coagulase-negative staphylococci (CoNS), identified at the Microbiology
Laboratory - UNIFESP. Design: Experimental laboratory investigation.
Methods: The minimum inhibitory concentrations (MICs) of 21 strains of
methicillin-resistant coagulase-negative staphylococci (MRCoNS) and 22
methicillin-sensitive coagulase-negative staphylococci (MSCoNS) to
ciprofloxacin, ofloxacin, gatifloxacin and moxifloxacin were determined,
using the E-test method standardized by the Clinical and Laboratory
Standards Institute (CLSI/NCCLS). Results: The MIC90s (µg/ml) for the
second generation of tested fluoroquinolones were higher than the
fourth generation, especially for the methicillin-resistant coagulase-
negative staphylococci group. Conclusion: Our results indicate that
methicillin-sensitive coagulase-negative staphylococci are more sus-
ceptible to quinolones than are methicillin-resistant coagulase-negative
staphylococci and that fourth generation fluoroquinolones appear to be
more potent, affecting even coagulase-negative staphylococcal strains
resistant to second generation fluoroquinolones.
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moxifloxacin and gatifloxacin) provide: broad-spectrum covera-
ge against most aerobic gram-negative and gram-positive bac-
teria, low toxicity, safety, good ocular surface penetration, pro-
longed tear film concentration, stability at room temperature,
and good availability(5,10). Unfortunately, recent reports of bac-
terial resistance to these second generation fluoroquinolones
have had an impact on their acceptance, with a decrease in their
use and the introduction of the fourth generation fluoroquino-
lones as an alternative to increase the spectrum of action,
mostly against gram-positive cocci(5,10-14).
Microbial resistance to fluoroquinolones is the result of
genetic changes in one or more of four major bacterial mecha-
nisms: enzymes for DNA synthesis; gyrase protecting pro-
teins; cell permeability or drug efflux(15).
The 8-methoxyfluoroquinolones, gatifloxacin and moxiflo-
xacin, have enhanced activity against gram-positive patho-
gens, thereby increasing the probability that strains resistant to
the older fluoroquinolones will be susceptible. These newer
fluoroquinolones are less prone to encourage the development
of resistance on a number of fronts, primarily because of their
higher activity against gram-positive pathogens, but for other
reasons as well, such as the necessity of two mutations: one in
the topoisomerase IV and a second in the DNA gyrase gene(12).
The purpose of this study was to evaluate and compare
the antibiotic susceptibility results of CoNS isolated from eye
infections at the Microbiology Laboratory of the Vision of
Institute, Federal University of São Paulo, Brazil.
METHODS
Forty-three CoNS ocular isolates were studied and divided in-
to two groups according to resistance to methicillin; these con-
sisted of 21 methicillin-resistant organisms (3 endophthalmitis, 10
keratitis and 8 conjunctivitis) and 22 methicillin-sensitive
organisms (11 endophthalmitis, 9 keratitis and 2 conjunctivitis).
Methicillin-resistance of the strains was determined by the
Kirby-Bauer disk diffusion method using 1 µg oxacillin disk
(Cecon, São Paulo, Brazil) according to the criteria of the
Clinical and Laboratory Standards Institute (CLSI/NCCLS)(16).
Antibiotic susceptibility of each bacterial isolate to cipro-
floxacin, ofloxacin, gatifloxacin and moxifloxacin was determi-
ned by two methods: Kirby-Bauer disk diffusion (Cecon, São
Paulo, Brazil) and E-test (AB Biodisk, Solna, Sweden)(14). In-
terpretation for susceptible and non-susceptible (intermediate
and resistant) responses were in accordance with the criteria
of the Clinical and Laboratory Standards Institute (CLSI/
NCCLS) document M100-S15, Vol. 25 Nº1NCCLS: ciprofloxacin
S= <1 µg/ml, R= >4 µg/ml; ofloxacin S= <1 µg/ml, R= >4 µg/ml;
gatifloxacin S= <0,5 µg/ml, R= >2 µg/ml; moxifloxacin S=
<0,5 µg/ml, R= >2 µg/ml(16).
Minimal inhibitory concentration 90s (MIC90) were deter-
minated for each group, methicillin-resistant and methicillin-
sensitive coagulase-negative staphylococci.
The results were statistically evaluated by the Mann-
Whitney and the Friedman tests.
RESULTS
Table 1 summarizes the MIC90 of the 21 methicillin-resis-
tant isolates and table 2 summarizes the MIC90s of the 22
methicillin-sensitive isolates to ciprofloxacin, ofloxacin, gati-
floxacin, and moxifloxacin.
For all tested antibiotics, MIC values were statistically
higher for the methicillin-resistant group than for the methicil-
lin-sensitive group (p<0.05) (Table 3).
Comparing the MIC values for the four antibiotics by the
Friedman test, those for ofloxacin were statistically significan-
tly higher in both groups: ofloxacin > ciprofloxacin > (gatiflo-
xacin=moxifloxacin) (p<0.001) (Table 3).
There was no statistically significantly difference between
both groups comparing the resistance of the four antibiotics
by the two methods (Tables 4 and 5).
Table 1. Susceptibilities of methicillin-resistant coagulase-negative
Staphylococcus isolates to fluoroquinolones
Range MIC90 % Sensitivity % Sensitivity
(µg/ml) (µg/ml) disc E-test
Cipro 0.047 – 32 32 52.4% 28.60%
Oflox 0.094 – 32 32 57.1% 23.80%
Gati 0.032 – 2.0 2.0 71.4% 38.10%
Moxi 0.023 – 3.0 3.0 81.0% 33.33%
MIC= minimum inhibitory concentrations; Cipro= ciprofloxacin; Oflox= ofloxacin;
Gati= gatifloxacin; Moxi= moxifloxacin
Table 2. Susceptibilities of methicillin-sensitive coagulase-negative
Staphylococcus isolates to fluoroquinolones
Range MIC90 % Sensitivity % Sensitivity
(µg/ml) (µg/ml) disc E-test
Cipro 0.064 – 0.250 0.250 095.5% 95.5%
Oflox 0.190 – 1.000 1.000 095.5% 90.9%
Gati 0.047 – 0.125 0.125 100.0% 95.5%
Moxi 0.032 – 0.125 0.125 095.5% 95.5%
MIC= minimum inhibitory concentrations; Cipro= ciprofloxacin; Oflox= ofloxacin;
Gati= gatifloxacin; Moxi= moxifloxacin
Table 3. Descriptives measurements: 1st and 3rd quartiles and medians
of MIC values of both groups
Antibiotics MR CoNS MS CoNS Mann-Whitney
(n=21) (n=22) test
Ciprofloxacin 0.820 – 7.000 0.125 – 0.190 p<0.001
3.00 0.158
Ofloxacin 1.190 – 32.000 0.250 – 0.500 p=0.001
8.00 0.380
Gatifloxacin 0.188 – 2.000 0.064 – 0.102 p<0.001
1.50 0.094
Moxifloxacin 0.380 – 1.750 0.064 – 0.094 p<0.001
1.00 0.094
MIC= minimum inhibitory concentrations; MR CoNS= Methicillin-resistant coa-
gulase-negative Staphylococcus; MS CoNS= Methicillin-susceptible coagulase-
negative Staphylococcus
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DISCUSSION
As has been well demonstrated in the infectious disease
literature, resistant strains are developing with increasing use
of an antibiotic(5). As a result, periodic susceptibility surveys
are important to detect emerging resistance patterns, which
may become clinically significant.
In the here described study, we examined the in vitro
susceptibility of coagulase-negative staphylococci to fluoro-
quinolone antibiotics. The MIC90 values for the methicillin-
resistant group were higher then those for the methicillin-
susceptible group. Both groups of staphylococci were more
susceptible to gatifloxacin and moxifloxacin than they were to
ciprofloxacin and ofloxacin.
The differences observed for the diffusion susceptibilities
compared with the E-test results for CoNS could be explained
by the fact that CLSI/NCCLS considers the standards for all
drugs with no deterrents regarding the species. Probably in
the future new studies would differentiate the level of antibio-
tic susceptibility based not on the group of CoNS but based
on the species.
In 2002, Mather and colleagues determined the median
MICs for 93 bacterial endophthalmitis isolates using the E-test
approach. The results of the study demonstrated that compa-
ring the median MICs for the fourth-generation agents, moxi-
floxacin was more potent than gatifloxacin against fluoroqui-
nolone susceptible CoNS; and equally potent against fluoro-
quinolone-resistant CoNS(17).
Our results are supported by those of Stroman and asso-
ciates, who similarly presented MIC data demonstrating the
high potency of moxifloxacin(18).
Some authors studying bacterial keratitis isolates, found
that fluoroquinolone-susceptible and resistant CoNS were
equally susceptible to the second and fourth generation. The
MIC of moxifloxacin was equivalent to that of gatifloxacin for
fluoroquinolone-resistant CoNS. In our study, the MIC90 was
lower for gatifloxacin than that of moxifloxacin for MR CoNS,
but equal for CoNS(13) (Tables 6 and 7).
Other authors published that ocular S. epidermidis retrie-
ved from conjunctivitis are clearly more susceptible to moxi-
Table 4. Antibiotic % susceptibilities of both groups by the Kirby-Bauer disk method
Groups Result Cipro Oflox Gati Moxi Friedman test
MR CoNS Not susceptible 10 (47.6%) 9 (42.9%) 6 (28.6%) 4 (19.0%) p=0.096
(n=21) Susceptible 11 (52.4%) 12 (57.1%) 15 (71.4%) 17 (81.0%)
MS CoNS Not susceptible 1 (04.5%) 1 (04.5%) 0 (00.0%) 1 (04.5%) p=0.733
(n=22) Susceptible  21 (95.5%) 21 (95.5%) 22 (100%) 21 (95.5%)
Cipro= ciprofloxacin; Oflox= ofloxacin; Gati= gatifloxacin; Moxi= moxifloxacin; MR CoNS= Methicillin-resistant coagulase-negative Staphylococcus; MS CoNS=
Methicillin-susceptible coagulase-negative Staphylococcus
Table 5. Antibiotic % susceptibilities of both groups using the E-test method
Groups Result Cipro Oflox Gati Moxi Friedman test
MR CoNS Not susceptible 15 (71.4%) 6 (76.2%) 13 (61.9%) 14 (66.7%) p=0.232
(n=21) Susceptible 6 (28.6%) 5 (23.8%) 8 (38.1%) 7 (33.3%)
MS CoNS Not susceptible 1 (04.5%) 2 (09.1%) 1 (04.5%) 1 (04.5%) p=0.392
(n=22) Susceptible 21 (95.5%) 20 (90.9%) 21 (95.5%) 21 (95.5%)
Cipro= ciprofloxacin; Oflox= ofloxacin; Gati= gatifloxacin; Moxi= moxifloxacin; MR CoNS= Methicillin-resistant coagulase-negative Staphylococcus; MS CoNS=
Methicillin-susceptible coagulase-negative Staphylococcus
Table 6. Comparison between MIC90 values in our studies and Kol-
waski’s 2003/USA(13)
MIC90
Moxi Gati Cipro Oflox
MR CoNS Brazil 3 2 32 32
Kolwaski 2003 3 3 64 64
MS CoNS Brazil 0.750 1 02 06
Kolwaski 2003 0.125 0.19 0.38 0.75
Moxi= moxifloxacin; Gati= gatifloxacin; Cipro= ciprofloxacin; Oflox= ofloxacin;
MR CoNS= Methicillin-resistant coagulase-negative Staphylococcus; MS CoNS=
Methicillin-susceptible coagulase-negative Staphylococcus
Table 7. MIC90 values and potency for coagulase-negative Staphylococcus isolates to fluoroquinolones
MIC90
n Potency Cipro Oflox Gati Moxi
MRCoNS 21 gati > moxi > cipro = oflox 32 32 2 3
MSCoNS 22 moxi > gati > cipro > oflox 0.25 1.0 0.125 0.125
MIC= minimum inhibitory concentrations; Cipro= ciprofloxacin; Oflox= ofloxacin; Gati= gatifloxacin; Moxi= moxifloxacin; MR CoNS= Methicillin-resistant coagulase-
negative Staphylococcus; MS CoNS= Methicillin-susceptible coagulase-negative Staphylococcus
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floxacin than ciprofloxacin throughout three different parts of
world (USA, Europe and India), based on the MIC90s(19).
Fluoroquinolone antibiotics are concentration-dependent
killers in that the MIC must be reached for the antibiotic to be
effective. These values are based on CLSI/NCCLS criteria rela-
ted to the drug concentration that is safely achievable in plas-
ma, and do not reflect the concentration achievable with topical
application. Therefore, some isolates classified as intermediate
or resistant might be sensitive if the ocular tissue levels are
much greater than those of serum. The CLSI/NCCLS standards
indicate also that systemic penetration for effective therapy is
similar among the fluoroquinolones tested in our study. It
would thus be reasonable to assume that similar, perhaps even
higher levels can be reached in the ocular tissues. If we assume
that antibiotic concentrations in ocular tissues following topi-
cal administration are at least equivalent to (if not higher than)
systemic penetration, the key parameter to consider in compa-
ring antibiotic effectiveness is the MIC value: the antibiotic
with the lowest MIC for a bacterial group would be the most
potent. Furthermore, the most potent antibiotic would have the
least chance of causing resistance because the concentration in
the ocular tissues would less likely be sublethal.
Primary use of the newer fluoroquinolones in preference to
use of the older fluoroquinolones provides the potential for
helping to forestall the development of resistance, but this
approach must be coupled with the overall strategy of avoi-
ding indiscriminate use of and ensuring proper dosing with
these antimicrobials(3).
CONCLUSION
Our in vitro study suggests that the fourth generation
fluoroquinolones are more potent than are the second and
third generation fluoroquinolones against coagulase-negati-
ve staphylococci, particularly those resistant to methicillin.
RESUMO
Objetivos: Avaliar a suscetibilidade a fluorquinolonas dos
Staphylococcus coagulase-negativo (SCoN) identificados no
Laboratório de Microbiologia Ocular da UNIFESP. Métodos:
Foi determinada a concentração inibitória mínima de 21 cepas
de SCoN meticilina-resistentes e 22 meticilina-sensíveis para
ciprofloxacina, ofloxacina, gatifloxacina e moxifloxacina, utili-
zando o E-test estandartizado pelo CLSI/NCCLS. Resultados:
Os MIC90 (µg/ml) de 43 SCoN isolados para fluorquinolonas
de segunda geração foram maiores do que os de quarta gera-
ção, principalmente para o grupo dos meticilina-resistentes.
Conclusão: Nossos resultados indicam que Staphylococcus
coagulase-negativo meticilina-sensíveis são mais suscetíveis
às quinolonas do que os Staphylococcus coagulase-negativo
meticilina-resistentes, fluorquinolonas de quarta geração pa-
recem ser mais potentes, cobrindo inclusive cepas de Staphy-
lococcus coagulase-negativo resistentes à segunda geração
de fluorquinolonas.
Descritores: Resistência microbiana a drogas; Infecções ocu-
lares bacterianas/microbiologia; Staphylococcus/isolamento
& purificação; Coagulase; Fluoroquinolonas; Resistência a
meticilina
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